InstitutionMD Anderson
DepartmentExperimental Therapeutics
Address1881 East Road
Houston TX 77054-3005
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Perez-Oquendo M, Romano G, Farris DP, Gandhi V, Wistuba II, Tillman RE, Udan R, Mangahas P, Soundararajan R. A structured curriculum supporting biomedical trainees' transition into independent academic positions and early career success. BMC Med Educ. 2024 Apr 08; 24(1):379. PMID: 38589919; PMCID: PMC11000405.
    2. Sexauer AN, Alexe G, Gustafsson K, Zanetakos E, Milosevic J, Ayres M, Gandhi V, Pikman Y, Stegmaier K, Sykes DB. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701. PMID: 37648673; PMCID: PMC10641474.
      Citations:    Fields:    Translation:HumansAnimalsCells
    3. Pullarkat V, Chen LS, Palmer J, Zhang J, Synold TW, Buettner R, Truong Nguyen LX, Marcucci G, Tsai NC, Wang Y, O'Hearn J, Gandhi V, Rosen ST. A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics. Cancer. 2024 03 01; 130(5):727-739. PMID: 37897709.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol. 2023; 13:1226289. PMID: 37601693; PMCID: PMC10436212.
      Citations: 2     
    5. Tantawy SI, Timofeeva N, Hernandez A, Sarkar A, Gandhi V. Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability. Oncotarget. 2023 06 21; 14:653-655. PMID: 37343064; PMCID: PMC10284423.
      Citations: 1     Fields:    Translation:HumansCells
    6. Timofeeva N, Ayres ML, Baran N, Santiago-O'Farrill JM, Bildik G, Lu Z, Konopleva M, Gandhi V. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Front Oncol. 2023; 13:1161254. PMID: 37228498; PMCID: PMC10203524.
      Citations: 2     
    7. Aslan B, Tantawy SI, Gandhi V. Curing CLL: one clone at a time. Blood Adv. 2023 05 09; 7(9):1926-1928. PMID: 36355806; PMCID: PMC10202734.
      Citations:    Fields:    Translation:HumansCells
    8. Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res. 2023 01 17; 29(2):446-457. PMID: 36346691; PMCID: PMC9852224.
      Citations: 3     Fields:    Translation:HumansCells
    9. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589. PMID: 36448227.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Demarest JF, Kienle M, Boytz R, Ayres M, Kim EJ, Patten JJ, Chung D, Gandhi V, Davey RA, Sykes DB, Shohdy N, Pottage JC, Kumar VS. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Antiviral Res. 2022 10; 206:105403. PMID: 36041646; PMCID: PMC9420051.
    11. Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 05 20; 12(5):80. PMID: 35595730; PMCID: PMC9123190.
      Citations:    Fields:    Translation:HumansAnimalsCells
    12. Hoang DH, Morales C, Rodriguez IR, Valerio M, Guo J, Chen MH, Wu X, Horne D, Gandhi V, Chen LS, Zhang B, Pullarkat V, Rosen ST, Marcucci G, Buettner R, Nguyen LXT. Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism. Cancers (Basel). 2022 Mar 11; 14(6). PMID: 35326597; PMCID: PMC8946614.
    13. Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Wierda W, Gandhi V, Keating M, Caligaris-Cappio F, Ghia P, Bertilaccio MTS, Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Scarf? L, Ponzoni M, Biondi A, Biagi E. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2022 07; 63(7):1566-1579. PMID: 35259043; PMCID: PMC9828187.
      Citations: 2     Fields:    Translation:HumansCells
    14. Teakell S, Chen LS, Stellrecht CM, Gandhi V. The role of p53 and p21 on 8-chloro-adenosine-induced cellular response. Nucleosides Nucleotides Nucleic Acids. 2022 Feb 28; 1-16. PMID: 35227162.
      Citations:    Fields:    
    15. Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:833714. PMID: 35273915; PMCID: PMC8901605.
    16. Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 01 01; 107(1):292-297. PMID: 34498444; PMCID: PMC8719067.
      Citations: 2     Fields:    Translation:HumansCells
    17. Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res. 2022 02; 20(2):280-292. PMID: 34654720; PMCID: PMC8816854.
      Citations: 2     Fields:    Translation:HumansCells
    18. Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. Development and characterization of prototypes for in?vitro and in?vivo mouse models of ibrutinib-resistant CLL. Blood Adv. 2021 08 24; 5(16):3134-3146. PMID: 34424317; PMCID: PMC8405195.
      Citations: 2     Fields:    Translation:HumansAnimals
    19. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383; PMCID: PMC8193546.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    20. Sarkar A, Gandhi V. Correction to: Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jul; 476(7):2887. PMID: 34021870.
      Citations: 1     Fields:    
    21. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    22. Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021 04 29; 11(4):79. PMID: 33927183; PMCID: PMC8085243.
      Citations: 7     Fields:    Translation:HumansAnimals
    23. Buettner R, Nguyen LXT, Morales C, Chen MH, Wu X, Chen LS, Hoang DH, Hernandez Vargas S, Pullarkat V, Gandhi V, Marcucci G, Rosen ST. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J Hematol Oncol. 2021 04 26; 14(1):70. PMID: 33902674; PMCID: PMC8074444.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    24. Groenland SL, Ratain MJ, Chen LS, Gandhi V. The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:92-106. PMID: 34010057.
      Citations:    Fields:    Translation:Humans
    25. Bose P, Gandhi V. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Fac Rev. 2021; 10:22. PMID: 33718939; PMCID: PMC7946394.
    26. Sarkar A, Stellrecht CM, Vangapandu HV, Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita TK, Hittelman WN, Neelapu SS, Gandhi V. Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. 2021 02 01; 106(2):495-512. PMID: 32029507; PMCID: PMC7849759.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    27. Timofeeva N, Gandhi V. Metabolism meets apoptosis in AML. Leuk Lymphoma. 2021 03; 62(3):514-516. PMID: 33356786.
      Citations:    Fields:    Translation:Humans
    28. Sarkar A, Gandhi V. Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jan; 476(1):417-423. PMID: 32996079; PMCID: PMC7867566.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    29. Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 07 15; 26(14):3856-3867. PMID: 31937611; PMCID: PMC7358119.
      Citations: 21     Fields:    Translation:HumansCells
    30. Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS, Scarf? L. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res. 2019 12; 7(12):2036-2051. PMID: 31530560; PMCID: PMC6891195.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    31. Jain N, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789. PMID: 31433937.
      Citations: 2     Fields:    Translation:Humans
    32. Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2019 12; 60(12):3063-3066. PMID: 31161836.
      Citations: 2     Fields:    Translation:Humans
    33. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    34. Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 07 01; 79(13):3251-3267. PMID: 31040157; PMCID: PMC6606351.
      Citations: 78     Fields:    Translation:HumansAnimalsCells
    35. Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget. 2019 Apr 19; 10(29):2793-2809. PMID: 31073371; PMCID: PMC6497463.
      Citations: 5     Fields:    
    36. Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST. 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia. J Cell Physiol. 2019 Sep; 234(9):16295-16303. PMID: 30770553; PMCID: PMC6697246.
      Citations: 6     Fields:    
    37. Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605. PMID: 30724681.
      Citations: 1     Fields:    Translation:Humans
    38. Aslan B, Ayres ML, Gandhi V. Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. Methods Mol Biol. 2019; 1881:19-25. PMID: 30350194.
      Citations:    Fields:    Translation:HumansCells
    39. Bertilaccio MTS, Zhang R, Banerjee P, Gandhi V. In Vitro Assay to Study CLL and Monocyte Interactions. Methods Mol Biol. 2019; 1881:113-119. PMID: 30350201.
      Citations: 1     Fields:    Translation:HumansCells
    40. Vangapandu HV, Gandhi V. Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. Methods Mol Biol. 2019; 1881:121-128. PMID: 30350202.
      Citations: 3     Fields:    Translation:HumansCells
    41. Chen W, Fan H, Balakrishnan K, Wang Y, Sun H, Fan Y, Gandhi V, Arnold LA, Peng X. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. J Med Chem. 2018 10 25; 61(20):9132-9145. PMID: 30247905.
      Citations: 10     Fields:    Translation:HumansCells
    42. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259. PMID: 30254130; PMCID: PMC6251009.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    43. Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018 09 01; 19(14):1101-1110. PMID: 30088438; PMCID: PMC6219441.
      Citations: 2     Fields:    Translation:Humans
    44. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. PMID: 30071517.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    45. Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 2018 May 18; 9(38):24980-24991. PMID: 29861847; PMCID: PMC5982765.
      Citations: 18     Fields:    
    46. Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018 05; 118(11):1425-1433. PMID: 29765150; PMCID: PMC5988656.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    47. Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930. PMID: 29099493; PMCID: PMC5871548.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    48. Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res. 2017; 6:1924. PMID: 29152232; PMCID: PMC5664994.
      Citations: 5     Fields:    
    49. Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma. 2018 06; 59(6):1427-1438. PMID: 28971726; PMCID: PMC5882591.
      Citations: 4     Fields:    Translation:HumansCells
    50. Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771. PMID: 28863345; PMCID: PMC5577399.
      Citations: 12     Fields:    Translation:HumansCells
    51. Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703. PMID: 28835371; PMCID: PMC5714317.
      Citations: 18     Fields:    Translation:HumansCells
    52. Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017 10; 179(2):266-271. PMID: 28737232; PMCID: PMC5638689.
      Citations: 10     Fields:    Translation:HumansCells
    53. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. PMID: 28718728; PMCID: PMC5773400.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    54. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931; PMCID: PMC5739034.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    55. Yang Q, Modi P, Korkut A, Fernandes SM, Hanna J, Brown JR, Gandhi V. Changes in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic Lymphocytic Leukemia Lymphocytes. JCO Precis Oncol. 2017; 1. PMID: 32913964; PMCID: PMC7446340.
      Citations: 1     Fields:    
    56. Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):625-632. PMID: 28388280; PMCID: PMC5584596.
      Citations: 21     Fields:    Translation:HumansAnimals
    57. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. PMID: 27655665; PMCID: PMC5400650.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    58. Wang Y, Fan H, Balakrishnan K, Lin Z, Cao S, Chen W, Fan Y, Guthrie QA, Sun H, Teske KA, Gandhi V, Arnold LA, Peng X. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. Eur J Med Chem. 2017 Jun 16; 133:197-207. PMID: 28388522; PMCID: PMC5652303.
      Citations: 6     Fields:    Translation:HumansCells
    59. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985. PMID: 28337527; PMCID: PMC5406425.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    60. Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274. PMID: 28187444; PMCID: PMC5369961.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    61. Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17. PMID: 28140720; PMCID: PMC5478500.
      Citations: 69     Fields:    Translation:HumansAnimals
    62. Gandhi V, Jalali R. A Conference of New Ideas in Cancer-Challenging Dogmas. Cancer Res. 2017 01 15; 77(2):234-237. PMID: 28062401.
      Citations:    Fields:    Translation:Humans
    63. Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743. PMID: 28034907; PMCID: PMC5491371.
      Citations: 45     Fields:    Translation:HumansCells
    64. Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. 2017 09; 31(9):1872-1881. PMID: 28017967; PMCID: PMC5540815.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    65. Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017 Jan; 10(1):1-8. PMID: 27869523; PMCID: PMC5578611.
      Citations: 10     Fields:    Translation:HumansAnimals
    66. Mendes VIS, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JAR. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331]. Eur J Med Chem. 2016 11 29; 124:1004-1005. PMID: 27783971; PMCID: PMC5654515.
      Citations:    Fields:    
    67. Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2016 10 13; 9(1):110. PMID: 27737688; PMCID: PMC5064904.
      Citations: 1     Fields:    
    68. Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016 Nov; 12(11):1381-1392. PMID: 27686109; PMCID: PMC5391303.
      Citations: 13     Fields:    
    69. Patel P, Vora H, Aggarwal BB, Gandhi V, Mehta K, Pathak S. Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference. Anticancer Res. 2016 09; 36(9):4971-5. PMID: 27630358.
      Citations:    Fields:    Translation:Humans
    70. Mendes VIS, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JAR. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. Eur J Med Chem. 2016 Nov 10; 123:317-331. PMID: 27484517; PMCID: PMC5652311.
      Citations: 12     Fields:    Translation:HumansCells
    71. Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472. PMID: 27223062; PMCID: PMC5129945.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    72. Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res. 2017 Jan 01; 23(1):181-192. PMID: 27342398; PMCID: PMC5433851.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    73. Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873. PMID: 27054578; PMCID: PMC5650058.
      Citations: 9     Fields:    Translation:HumansCells
    74. Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res. 2016 Sep 15; 22(18):4712-26. PMID: 27026200; PMCID: PMC5118040.
      Citations: 12     Fields:    Translation:HumansCells
    75. Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):3461-76. PMID: 26658105; PMCID: PMC4823120.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    76. Patel V, Keating MJ, Wierda WG, Gandhi V. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(6):1494-7. PMID: 26440741; PMCID: PMC4963009.
      Citations: 9     Fields:    Translation:HumansCells
    77. Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2016 Feb; 57(2):436-444. PMID: 26088877; PMCID: PMC4814351.
      Citations: 6     Fields:    
    78. Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One. 2015; 10(8):e0135962. PMID: 26313261; PMCID: PMC4552467.
      Citations: 6     Fields:    Translation:HumansCells
    79. Zaman S, Wang R, Gandhi V. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Exp Hematol. 2015 Nov; 43(11):951-962.e3. PMID: 26257207; PMCID: PMC4630139.
      Citations: 6     Fields:    Translation:HumansCells
    80. Wang J, Yin H, Panandikar A, Gandhi V, Sen S. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug; 47(2):782-90. PMID: 26058363; PMCID: PMC4501665.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    81. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22. PMID: 25917267; PMCID: PMC4558374.
      Citations: 75     Fields:    Translation:HumansCells
    82. Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15. PMID: 25829398; PMCID: PMC4537801.
      Citations: 91     Fields:    Translation:HumansCells
    83. Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300. PMID: 25810013; PMCID: PMC4372650.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    84. Yang Q, Modi P, Newcomb T, Gandhi V, Qu?va C. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res. 2015 Apr 01; 21(7):1537-42. PMID: 25670221; PMCID: PMC4523214.
      Citations: 77     Fields:    Translation:Humans
    85. Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10. PMID: 25573971; PMCID: PMC4287645.
      Citations: 13     Fields:    Translation:HumansCells
    86. Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36. PMID: 25538042; PMCID: PMC4326772.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    87. Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46. PMID: 25499217; PMCID: PMC4309260.
      Citations: 20     Fields:    Translation:HumansCells
    88. Mehta K, Gandhi V, Pathak S, Aggarwal BB, Grover RK. Multi-targeted approach to cancer treatment: an international translational cancer research symposium. Anticancer Res. 2014 Nov; 34(11):6791-5. PMID: 25368293.
      Citations: 4     Fields:    Translation:HumansCells
    89. Chen LS, Keating MJ, Gandhi V. Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. Blood. 2014 Aug 14; 124(7):1192-5. PMID: 25124785; PMCID: PMC4133491.
      Citations: 2     Fields:    Translation:Humans
    90. Chen W, Balakrishnan K, Kuang Y, Han Y, Fu M, Gandhi V, Peng X. Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem. 2014 Jun 12; 57(11):4498-510. PMID: 24801734; PMCID: PMC4133937.
      Citations: 23     Fields:    Translation:HumansCells
    91. El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3780-9. PMID: 24747434; PMCID: PMC4055925.
      Citations: 13     Fields:    Translation:HumansCells
    92. Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40. PMID: 24501394; PMCID: PMC4048124.
      Citations: 43     Fields:    Translation:HumansCells
    93. Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014 Sep; 55(9):1980-92. PMID: 24295132; PMCID: PMC4152229.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    94. Yang Q, Chen LS, Gandhi V. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des. 2014; 20(42):6670-81. PMID: 25341939.
      Citations: 1     Fields:    Translation:HumansAnimals
    95. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8. PMID: 24440659; PMCID: PMC4182922.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    96. Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92. PMID: 24326130; PMCID: PMC3878866.
      Citations: 11     Fields:    Translation:HumansCells
    97. Balakrishnan K, Gandhi V. Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy. Leuk Lymphoma. 2013 Dec; 54(12):2581-3. PMID: 23656199.
      Citations:    Fields:    Translation:Humans
    98. Gandhi V. A new feature in Leukemia & Lymphoma: "Emerging drug profile". Leuk Lymphoma. 2013 Oct; 54(10):2131-2. PMID: 24041378.
      Citations:    Fields:    Translation:Humans
    99. Patel V, Chen LS, Wierda WG, Balakrishnan K, Gandhi V. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):899-910. PMID: 23837491; PMCID: PMC4172382.
      Citations: 14     Fields:    Translation:HumansCells
    100. Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66. PMID: 24024897; PMCID: PMC3860742.
      Citations: 17     Fields:    Translation:HumansCells
    101. Yang Q, Chen LS, Neelapu SS, Gandhi V. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S355-62. PMID: 24290221; PMCID: PMC3951504.
      Citations: 9     Fields:    Translation:HumansCells
    102. Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29. PMID: 23988451; PMCID: PMC3951475.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    103. Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct; 31(5):1384-94. PMID: 23907405; PMCID: PMC4152228.
      Citations: 17     Fields:    Translation:HumansAnimals
    104. DiNardo CD, O'Brien S, Gandhi VV, Ravandi F. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol. 2013 Aug; 9(8):1073-82. PMID: 23902239.
      Citations: 4     Fields:    Translation:Humans
    105. Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Apr; 55(4):876-83. PMID: 23772636; PMCID: PMC4102412.
      Citations: 2     Fields:    Translation:HumansCells
    106. Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):458-66. PMID: 23773454; PMCID: PMC4102435.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    107. Gandhi V, Mehta K, Pathak S, Aggarwal BB. Meeting report: leaders in translational cancer research meet in Udaipur, a historical town of India: an International Symposium onTranslational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, december 16-19, 2011. Anticancer Res. 2013 Apr; 33(4):1777-81. PMID: 23564834.
      Citations:    Fields:    Translation:HumansAnimalsCells
    108. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115; PMCID: PMC3567921.
      Citations: 463     Fields:    Translation:HumansAnimalsCells
    109. Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012 Oct 25; 120(17):3491-500. PMID: 22955922; PMCID: PMC3482859.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    110. Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100. PMID: 22866921; PMCID: PMC4123740.
      Citations: 8     Fields:    Translation:HumansAnimals
    111. McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST. Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One. 2012; 7(7):e41455. PMID: 22848499; PMCID: PMC3407247.
      Citations: 9     Fields:    Translation:HumansCells
    112. Peng X, Gandhi V. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage. Ther Deliv. 2012 Jul; 3(7):823-33. PMID: 22900465; PMCID: PMC3566582.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    113. Gandhi V, Balakrishnan K. CCL2 in chronic lymphocytic leukemia: a macro in microenvironment? Leuk Lymphoma. 2012 Oct; 53(10):1849-50. PMID: 22563818; PMCID: PMC4123321.
      Citations: 2     Fields:    Translation:Humans
    114. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616; PMCID: PMC3859239.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    115. Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct; 53(10):2024-32. PMID: 22448923; PMCID: PMC5648543.
      Citations: 1     Fields:    Translation:HumansCells
    116. Balakrishnan K, Gandhi V. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012 Apr; 21(4):409-23. PMID: 22409342; PMCID: PMC4142764.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    117. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9. PMID: 22180443; PMCID: PMC4916557.
      Citations: 299     Fields:    Translation:HumansAnimalsCells
    118. Tam CS, Gandhi V. Modifying the immune system to treat chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Feb; 53(2):177-8. PMID: 21895547.
      Citations:    Fields:    Translation:Humans
    119. Kuang Y, Balakrishnan K, Gandhi V, Peng X. Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc. 2011 Dec 07; 133(48):19278-81. PMID: 22035519; PMCID: PMC3265938.
      Citations: 56     Fields:    Translation:HumansCells
    120. Cervantes-Gomez F, Nimmanapalli R, Gandhi V. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther. 2011 Nov; 339(2):545-54. PMID: 21821695; PMCID: PMC3199983.
      Citations: 4     Fields:    Translation:HumansCells
    121. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8. PMID: 21751197; PMCID: PMC4180241.
      Citations: 12     Fields:    Translation:Humans
    122. Balakrishnan K, Gandhi V. The micros in harmony: microRNA and microenvironment. Leuk Lymphoma. 2011 Sep; 52(9):1626-9. PMID: 21740342.
      Citations:    Fields:    Translation:HumansCells
    123. Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23. PMID: 21712425; PMCID: PMC3186292.
      Citations: 28     Fields:    Translation:HumansCells
    124. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702. PMID: 21628411; PMCID: PMC3142906.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    125. Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics. 2011 Mar; 12(3):327-39. PMID: 21449673; PMCID: PMC3139433.
      Citations: 14     Fields:    Translation:Humans
    126. Zhang H, Gogada R, Yadav N, Lella RK, Badeaux M, Ayres M, Gandhi V, Tang DG, Chandra D. Defective molecular timer in the absence of nucleotides leads to inefficient caspase activation. PLoS One. 2011 Jan 27; 6(1):e16379. PMID: 21297999; PMCID: PMC3029307.
      Citations: 8     Fields:    Translation:HumansCells
    127. Gandhi V. Yet another nucleoside analog for pancreatic cancer. Gastroenterology. 2011 Feb; 140(2):400-4. PMID: 21172332.
      Citations:    Fields:    Translation:HumansAnimalsCells
    128. Gandhi V. Targeting kinases in CML CLL. Blood. 2010 Sep 23; 116(12):1999-2000. PMID: 20864583.
      Citations:    Fields:    
    129. Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood. 2010 Dec 16; 116(25):5622-30. PMID: 20844237; PMCID: PMC3031409.
      Citations: 13     Fields:    Translation:HumansCells
    130. Chen LS, Balakrishnan K, Gandhi V. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol. 2010 Dec 15; 80(12):1936-45. PMID: 20696142; PMCID: PMC3749885.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    131. Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug; 6(8):1211-7. PMID: 20799866.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    132. Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010 Aug 15; 70(16):6587-97. PMID: 20663900; PMCID: PMC2929954.
      Citations: 16     Fields:    Translation:HumansCells
    133. Gandhi V, Mehta K, Pathak S, Ravindran B, Mishra S, Aggarwal BB. City of temples discusses signaling templates in cancer cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy. Bhubaneswar, Orissa, India, December 18th through 21st, 2009. Anticancer Res. 2010 Jun; 30(6):2477-80. PMID: 20651411.
      Citations:    Fields:    Translation:HumansAnimalsCells
    134. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91. PMID: 20442367; PMCID: PMC2938131.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    135. Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia. 2010 May; 12(5):366-75. PMID: 20454508; PMCID: PMC2864474.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    136. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92. PMID: 20427701; PMCID: PMC2924226.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    137. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60. PMID: 20421540; PMCID: PMC4872315.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    138. Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem. 2010 Mar 12; 285(11):8022-30. PMID: 20064937; PMCID: PMC2832953.
      Citations: 6     Fields:    Translation:HumansCells
    139. Frey JA, Gandhi V. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther. 2010 Jan; 9(1):236-45. PMID: 20053765; PMCID: PMC2806509.
      Citations: 10     Fields:    Translation:HumansCells
    140. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009 Dec 15; 15(24):7456-7461. PMID: 19996200; PMCID: PMC2795094.
      Citations: 12     Fields:    
    141. Chen LS, Du-Cuny L, Vethantham V, Hawke DH, Manley JL, Zhang S, Gandhi V. Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol. 2010 Mar 01; 79(5):669-77. PMID: 19814999; PMCID: PMC2812641.
      Citations: 13     Fields:    Translation:Animals
    142. Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009 Sep 17; 114(12):2560-1; author reply 2561-2. PMID: 19762501; PMCID: PMC4969051.
      Citations: 9     Fields:    Translation:Humans
    143. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Gandhi V, Kay NE, Plunkett W, Burger JA, J?ger U. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. PMID: 19762485; PMCID: PMC4081374.
      Citations: 151     Fields:    Translation:HumansAnimalsCells
    144. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009 Nov 05; 114(19):4150-7. PMID: 19734450; PMCID: PMC2774551.
      Citations: 85     Fields:    Translation:HumansCells
    145. Dennison JB, Balakrishnan K, Gandhi V. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol. 2009 Nov; 147(3):297-307. PMID: 19709085; PMCID: PMC2778754.
      Citations: 22     Fields:    Translation:HumansCells
    146. Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem. 2009 Sep 25; 284(39):26816-30. PMID: 19648108; PMCID: PMC2785370.
      Citations: 25     Fields:    Translation:HumansCells
    147. Stellrecht CM, Ayres M, Arya R, Gandhi V. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat. 2010 Jun; 121(2):355-64. PMID: 19641990; PMCID: PMC5739050.
      Citations: 18     Fields:    Translation:HumansCells
    148. Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, Lamba J. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics. 2009 Aug 15; 25(16):2013-9. PMID: 19528086; PMCID: PMC2723006.
      Citations: 9     Fields:    
    149. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37. PMID: 19491390; PMCID: PMC4916941.
      Citations: 103     Fields:    Translation:HumansAnimalsCells
    150. Chen LS, Nowak BJ, Ayres ML, Krett NL, Rosen ST, Zhang S, Gandhi V. Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem Pharmacol. 2009 Sep 15; 78(6):583-91. PMID: 19477165; PMCID: PMC2763632.
      Citations: 17     Fields:    Translation:Cells
    151. Stellrecht CM, Gandhi V. Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma. 2009 May; 50(5):691-3. PMID: 19347768.
      Citations: 2     Fields:    Translation:Humans
    152. Cervantes-Gomez F, Nimmanapalli R, Gandhi V. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d. Cancer Res. 2009 May 01; 69(9):3947-54. PMID: 19383903; PMCID: PMC2778753.
      Citations: 6     Fields:    Translation:HumansCells
    153. Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, Raimondi SC, Downing JR, Razzouk BI, Pui CH, Ribeiro RC. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009 Aug; 23(8):1410-6. PMID: 19242495; PMCID: PMC2726271.
      Citations: 27     Fields:    Translation:Humans
    154. Guo Y, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M, K?ck K. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res. 2009 Mar 01; 15(5):1762-9. PMID: 19240178; PMCID: PMC5744661.
      Citations: 32     Fields:    Translation:HumansCells
    155. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45. PMID: 19234140; PMCID: PMC2680368.
      Citations: 79     Fields:    Translation:HumansCells
    156. Sampath D, Gandhi V. Dialing resistance up a Notch. Leuk Lymphoma. 2009 Feb; 50(2):158-9. PMID: 19235014.
      Citations:    Fields:    Translation:HumansCells
    157. Gandhi V, S?nchez-Vega B. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). Br J Haematol. 2009 Mar; 144(6):856-64. PMID: 19133980; PMCID: PMC4303606.
      Citations: 10     Fields:    Translation:HumansCells
    158. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 2009 Jul 18; 280(1):1-14. PMID: 19100682.
      Citations: 18     Fields:    Translation:HumansCells
    159. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5. PMID: 18932257; PMCID: PMC4126078.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    160. Gandhi V, Balakrishnan K, Chen LS. Mcl-1: the 1 in CLL. Blood. 2008 Nov 01; 112(9):3538-40. PMID: 18948586.
      Citations: 16     Fields:    
    161. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53. PMID: 18836097; PMCID: PMC2614629.
      Citations: 68     Fields:    Translation:HumansCells
    162. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2008 Sep 01; 112(5):1971-80. PMID: 18566329; PMCID: PMC2518898.
      Citations: 38     Fields:    Translation:HumansCells
    163. Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 2009 Mar; 63(4):587-97. PMID: 18509644; PMCID: PMC2892885.
      Citations: 11     Fields:    Translation:HumansCells
    164. Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol. 2008 Aug; 142(4):551-61. PMID: 18503584; PMCID: PMC4503206.
      Citations: 21     Fields:    Translation:HumansCells
    165. Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res. 2008 Oct; 32(10):1573-81. PMID: 18433867; PMCID: PMC4048126.
      Citations: 4     Fields:    Translation:Cells
    166. Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol. 2008 Mar; 15(2):101-7. PMID: 18300755.
      Citations: 4     Fields:    Translation:Humans
    167. Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO, Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 01; 26(7):1098-105. PMID: 18309944.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    168. Chen LS, Stellrecht CM, Gandhi V. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol. 2008 Mar; 140(6):682-391. PMID: 18205859.
      Citations: 25     Fields:    Translation:HumansCells
    169. Gandhi V. Questions about gemcitabine dose rate: answered or unanswered? J Clin Oncol. 2007 Dec 20; 25(36):5691-4. PMID: 18089862.
      Citations: 5     Fields:    Translation:Humans
    170. Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S8-12. PMID: 18086347.
      Citations: 11     Fields:    Translation:HumansCells
    171. Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007 Oct 15; 67(20):9913-20. PMID: 17942923.
      Citations: 21     Fields:    Translation:Humans
    172. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA. miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007 Oct; 3(5):521-37. PMID: 17927518.
      Citations: 47     Fields:    Translation:HumansAnimals
    173. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct; 48(10):1922-30. PMID: 17852710.
      Citations: 25     Fields:    Translation:HumansAnimals
    174. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45. PMID: 17855478.
      Citations: 42     Fields:    Translation:HumansCells
    175. Flanagan SA, Gandhi V, Meckling KA. Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leuk Lymphoma. 2007 Sep; 48(9):1816-27. PMID: 17786719.
      Citations: 3     Fields:    Translation:HumansCells
    176. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15; 110(6):1762-9. PMID: 17562873; PMCID: PMC1976362.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    177. Gandhi V. p53 as a predictor for chemotherapy response in CLL cells. Leuk Lymphoma. 2007 Feb; 48(2):219-20. PMID: 17325877.
      Citations: 1     Fields:    Translation:Humans
    178. Ravandi F, Gandhi V. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006 Dec; 15(12):1601-13. PMID: 17107284.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    179. Krett N, Rosen ST, Gandhi V, S?nchez-Vega B. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther. 2006 Dec; 5(12):3062-70. PMID: 17172408.
      Citations: 16     Fields:    Translation:HumansCells
    180. Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood. 2007 Mar 15; 109(6):2557-64. PMID: 17119117.
      Citations: 14     Fields:    Translation:HumansCells
    181. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66. PMID: 17108134.
      Citations: 30     Fields:    Translation:HumansCells
    182. Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006 Nov; 18(6):584-90. PMID: 16988579.
      Citations: 13     Fields:    Translation:Humans
    183. Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 01; 12(13):4011-7. PMID: 16818700.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    184. Chandra D, Bratton SB, Person MD, Tian Y, Martin AG, Ayres M, Fearnhead HO, Gandhi V, Tang DG. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell. 2006 Jun 30; 125(7):1333-46. PMID: 16814719.
      Citations: 55     Fields:    Translation:HumansCells
    185. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 01; 108(7):2392-8. PMID: 16778146; PMCID: PMC1895565.
      Citations: 27     Fields:    Translation:HumansCells
    186. Mehta K, Gandhi V, Aggarwal BB. All pathways to cancer apoptosis meeting in Thiruvananthapuram (India). Cell Death Differ. 2006 Dec; 13(12):2163-4. PMID: 16741526.
      Citations:    Fields:    Translation:HumansAnimalsCells
    187. Gandhi V, Keating MJ, Bate G, Kirkpatrick P. Nelarabine. Nat Rev Drug Discov. 2006 Jan; 5(1):17-8. PMID: 16485343.
      Citations: 9     Fields:    Translation:HumansCells
    188. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24. PMID: 16293603; PMCID: PMC1895741.
      Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
    189. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52. PMID: 16166456.
      Citations: 9     Fields:    Translation:HumansCells
    190. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60. PMID: 16131572; PMCID: PMC1895256.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    191. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
      Citations: 4     Fields:    Translation:Humans
    192. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 01; 106(7):2513-9. PMID: 15972445; PMCID: PMC1895272.
      Citations: 116     Fields:    Translation:HumansCells
    193. Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005 May 20; 23(15):3396-403. PMID: 15908652.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    194. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95. PMID: 15803490.
      Citations: 22     Fields:    Translation:Humans
    195. Ghias K, Ma C, Gandhi V, Platanias LC, Krett NL, Rosen ST. 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther. 2005 Apr; 4(4):569-77. PMID: 15827330.
      Citations: 15     Fields:    Translation:HumansCells
    196. Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62. PMID: 15718423; PMCID: PMC1895042.
      Citations: 26     Fields:    Translation:HumansCells
    197. Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22. PMID: 15496649.
      Citations: 12     Fields:    Translation:Humans
    198. Krett NL, Davies KM, Ayres M, Ma C, Nabhan C, Gandhi V, Rosen ST. 8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther. 2004 Nov; 3(11):1411-20. PMID: 15542780.
      Citations: 15     Fields:    Translation:HumansCells
    199. Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):361-368. PMID: 15723262.
      Citations: 27     Fields:    Translation:HumansCells
    200. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7. PMID: 15486072.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    201. Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23. PMID: 15571270.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    202. Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol. 2004 Aug; 54(2):113-21. PMID: 15133625.
      Citations: 4     Fields:    Translation:HumansCells
    203. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42. PMID: 14695132.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    204. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83. PMID: 12921943.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    205. Stellrecht CM, Rodriguez CO, Ayres M, Gandhi V. RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res. 2003 Nov 15; 63(22):7968-74. PMID: 14633728.
      Citations: 28     Fields:    Translation:HumansCells
    206. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9. PMID: 14551141.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    207. Flanagan SA, Gandhi V, Secrist JA, Meckling KA. The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol. 2003 Sep 01; 66(5):733-7. PMID: 12948853.
      Citations: 1     Fields:    Translation:HumansCells
    208. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86. PMID: 12791647.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    209. Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003 Sep 01; 102(5):1842-8. PMID: 12750168.
      Citations: 31     Fields:    Translation:HumansCells
    210. Wright K, Popli S, Gandhi VC, Lentino JR, Reyes CV, Leehey DJ. Paecilomyces peritonitis: case report and review of the literature. Clin Nephrol. 2003 Apr; 59(4):305-10. PMID: 12708573.
      Citations: 5     Fields:    Translation:HumansAnimals
    211. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73. PMID: 12637486.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    212. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, Iliakis G, Shay JW, Young CS, Pandita TK. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 2003 Jan 09; 22(1):131-46. PMID: 12527915.
      Citations: 86     Fields:    Translation:HumansCells
    213. Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther. 2002 Nov; 1(13):1221-7. PMID: 12479703.
      Citations: 11     Fields:    Translation:HumansCells
    214. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24. PMID: 12377965.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    215. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002 Aug; 29(4 Suppl 13):4-11. PMID: 12170425.
      Citations: 33     Fields:    Translation:HumansCells
    216. Gandhi V, Chen W, Ayres M, Rhie JK, Madden TL, Newman RA. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002 Aug; 50(2):85-94. PMID: 12172971.
      Citations: 10     Fields:    Translation:AnimalsCells
    217. Rodriguez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002 Jun 01; 62(11):3100-5. PMID: 12036920.
      Citations: 24     Fields:    Translation:HumansCells
    218. Lin-Lee YC, Nakamura S, Gandhi V, Curley SA, Burkot TR, Kuo MT, St?ber D. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. Mol Cancer Ther. 2002 May; 1(7):461-7. PMID: 12479264.
      Citations: 2     Fields:    Translation:HumansCells
    219. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002 Feb 01; 20(3):665-73. PMID: 11821446.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    220. Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58. PMID: 12703199.
      Citations: 1     Fields:    Translation:HumansAnimals
    221. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41(2):93-103. PMID: 11888330.
      Citations: 83     Fields:    Translation:HumansCells
    222. Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2002 Jan; 61(1):222-9. PMID: 11752224.
      Citations: 7     Fields:    Translation:HumansCells
    223. Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001 Nov; 13(6):514-21. PMID: 11673693.
      Citations: 9     Fields:    Translation:HumansCells
    224. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9. PMID: 11481354.
      Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
    225. Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res. 2001 Jul 15; 61(14):5474-9. PMID: 11454694.
      Citations: 40     Fields:    Translation:HumansCells
    226. Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001 Apr 15; 19(8):2142-52. PMID: 11304766.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    227. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif. 2001; 19:21-45. PMID: 11686015.
      Citations: 15     Fields:    Translation:HumansAnimals
    228. Rodriguez CO, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18; 745(2):421-30. PMID: 11043760.
      Citations: 9     Fields:    Translation:HumansCells
    229. Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000 Mar; 18(5):995-1003. PMID: 10694549.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    230. Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65. PMID: 10613450.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    231. Rodriguez CO, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999 Oct 01; 59(19):4937-43. PMID: 10519407.
      Citations: 15     Fields:    Translation:HumansCells
    232. Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, MacKey J, Dumontet C. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999 Jul; 106(1):78-85. PMID: 10444166.
      Citations: 30     Fields:    Translation:HumansCells
    233. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64. PMID: 9921974.
      Citations: 5     Fields:    Translation:HumansCells
    234. Gandhi V, Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998 Nov; 16(11):3607-15. PMID: 9817282.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    235. Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31. PMID: 9667246.
      Citations: 11     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    236. Gandhi V, Xu YZ, Estey E. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res. 1998 Jul; 4(7):1719-26. PMID: 9676847.
      Citations: 5     Fields:    Translation:Humans
    237. Rodriguez CO, Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Clin Cancer Res. 1997 Nov; 3(11):2107-13. PMID: 9815603.
      Citations: 4     Fields:    Translation:Humans
    238. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45. PMID: 9815841.
      Citations: 13     Fields:    Translation:HumansCells
    239. Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res. 1997 Aug; 3(8):1347-55. PMID: 9815818.
      Citations: 9     Fields:    Translation:HumansCells
    240. Plunkett W, Gandhi V. Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S67-74. PMID: 9137959.
      Citations: 1     Fields:    Translation:HumansAnimals
    241. Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91. PMID: 9137961.
      Citations: 3     Fields:    Translation:Humans
    242. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 1996 Oct 01; 56(19):4453-9. PMID: 8813140.
      Citations: 21     Fields:    
    243. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9. PMID: 8847890.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    244. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15. PMID: 8893876.
      Citations: 96     Fields:    Translation:HumansAnimals
    245. Gandhi V, Estey EH, Keating MJ, Plunkett W. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79. PMID: 8691580.
      Citations:    Fields:    Translation:Humans
    246. Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8. PMID: 9816215.
      Citations: 12     Fields:    Translation:HumansCells
    247. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64. PMID: 8547650.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    248. Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996; 38(3):261-8. PMID: 8646801.
      Citations: 1     Fields:    Translation:HumansCells
    249. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13. PMID: 8718419.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    250. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10. PMID: 7481842.
      Citations: 218     Fields:    Translation:HumansAnimalsCells
    251. Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7. PMID: 7481847.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    252. Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24. PMID: 7533664.
      Citations: 9     Fields:    Translation:AnimalsCells
    253. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb; 1(2):169-78. PMID: 9815970.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    254. Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8. PMID: 8090026.
      Citations:    Fields:    Translation:HumansCells
    255. Plunkett W, Gandhi V. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs. 1994; 47 Suppl 6:30-8. PMID: 7525187.
      Citations: 2     Fields:    Translation:HumansAnimals
    256. Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24. PMID: 7544948.
      Citations: 2     Fields:    Translation:Humans
    257. Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9. PMID: 7881348.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    258. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39. PMID: 7510070.
      Citations: 5     Fields:    Translation:HumansAnimals
    259. Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6. PMID: 8174200.
      Citations: 4     Fields:    Translation:Humans
    260. Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 Suppl 2:79-83. PMID: 8204523.
      Citations: 2     Fields:    Translation:HumansCells
    261. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6. PMID: 7533576.
      Citations: 2     Fields:    Translation:Humans
    262. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20. PMID: 7694371.
      Citations: 1     Fields:    Translation:Humans
    263. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):2-12. PMID: 8235690.
      Citations: 30     Fields:    Translation:Humans
    264. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60. PMID: 8374873.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    265. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May; 10(1-2):49-56. PMID: 8374523.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    266. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50. PMID: 8394169.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    267. Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb; 20(1):50-63. PMID: 8475410.
      Citations: 10     Fields:    Translation:Humans
    268. Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma. 1993; 11 Suppl 2:7-13. PMID: 8124234.
      Citations:    Fields:    Translation:Humans
    269. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan; 11(1):116-24. PMID: 8418222.
      Citations: 64     Fields:    Translation:Humans
    270. Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14. PMID: 8481660.
      Citations: 14     Fields:    Translation:Humans
    271. Yu AW, Soundararajan R, Nawab ZM, Gandhi VC, Rahman MA, Popli S, Ing TS. Raising plasma phosphorus levels by phosphorus-enriched, bicarbonate-containing dialysate in hemodialysis patients. Artif Organs. 1992 Aug; 16(4):414-6. PMID: 10078284.
      Citations:    Fields:    Translation:Humans
    272. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903. PMID: 1737352.
      Citations: 18     Fields:    Translation:HumansCells
    273. Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7. PMID: 1458554.
      Citations: 4     Fields:    Translation:HumansCells
    274. Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992; 31(3):193-9. PMID: 1464155.
      Citations: 5     Fields:    Translation:HumansCells
    275. Yu AW, Manahan FJ, Filkins JP, Mohammed MS, Soundararajan R, McShane AP, Gandhi VC, Ing TS. Peritoneal dialysis using bicarbonate-containing solution sterilized by ultrafiltration. Int J Artif Organs. 1991 Aug; 14(8):463-5. PMID: 1937936.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    276. Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30. PMID: 1789190.
      Citations: 5     Fields:    Translation:HumansCells
    277. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17. PMID: 1699280.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    278. Gandhi V, Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990 Jun 15; 50(12):3675-80. PMID: 2340517.
      Citations: 35     Fields:    Translation:HumansCells
    279. Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5. PMID: 2478221.
      Citations: 11     Fields:    Translation:HumansCells
    280. Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8. PMID: 2479383.
      Citations: 3     Fields:    Translation:HumansCells
    281. Gandhi VC, Jones DJ. Identification and characterization of [3H]nitrendipine binding sites in rat spinal cord. J Pharmacol Exp Ther. 1988 Nov; 247(2):473-80. PMID: 2460614.
      Citations: 1     Fields:    Translation:Animals
    282. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34. PMID: 3335008.
      Citations: 27     Fields:    Translation:HumansCells
    283. Gandhi VC, Ross DH. A novel kappa agonist inhibits [3H]nimodipine binding to a Ca++ channel receptor protein in rat brain. Biochem Biophys Res Commun. 1987 Dec 31; 149(3):1042-8. PMID: 2447885.
      Citations:    Fields:    Translation:AnimalsCells
    284. Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43. PMID: 3478543.
      Citations: 14     Fields:    Translation:HumansCells
    285. Gandhi V, Danhauser L, Plunkett W. Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23; 413:293-9. PMID: 3558682.
      Citations: 6     Fields:    Translation:HumansCells
    286. Sharp ZD, Gandhi VV, Procunier JD. X chromosome nucleolus organizer mutants which alter major type I repeat multiplicity in Drosophila melanogaster. Mol Gen Genet. 1983; 190(3):438-43. PMID: 6308398.
      Citations: 6     Fields:    Translation:AnimalsCells
    287. Gandhi VV, Sharp ZD, Procunier JD. Analysis of Y chromosome nucleolar organizer mutants in Drosophila melanogaster. Biochem Biophys Res Commun. 1982 Jan 29; 104(2):778-84. PMID: 6803790.
      Citations: 4     Fields:    Translation:AnimalsCells
    288. Bendamustine in B-cell malignancies. Clinical Cancer Research. 15:7456-7461.
    289. Clofarabine in paediatric patients with acute lymphoblastic leukaemia. Drugs and Therapy Perspectives. 22:3-5.
    290. 2',2'-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides and Nucleotides. 8:775-785.
    291. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clinical Cancer Research. 21:3705-3715.
    292. Gemcitabine. Nucleosides and Nucleotides. 16:1261-1270.
    293. Erratum. European Journal of Medicinal Chemistry. 124:1004-1005.
    294. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clinical Cancer Research. 22:4712-4726.
    295. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Experimental Hematology. 43:951-962.e3.
    296. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leukemia and Lymphoma. 57:436-444.
    297. Pim kinases in aml. 177-199.
    298. Histological and Histochemical Studies on the Cotyledons of Some Legumes II. Reserve metabolites during seed development. Cytologia. 52:847-858.
    300. Does ATP promote or protect cells from apoptosis?. Cancer Biology and Therapy. 5:712.
    301. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Metabolism and Toxicology. 1-12.
    302. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leukemia and Lymphoma.
    303. Idelalisib. Clinical Cancer Research. 21:1537-1542.
    304. 8-chloroadenosine sensitivity in renal cell carcinoma is associated with AMPK activation and mTOR pathway inhibition. PLoS One. 10.
    305. Forodesine. Haematologica Meeting Reports. 3:70.
    306. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Review of Hematology. 10:1-8.
    307. Cellular pharmacodynamics as a guide to leukemia therapy. Cancer Bulletin. 46:8-14.
    308. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 7:3461-3476.
    309. Erratum. Future Oncology. 11:1584.
    310. Mass propagation and genetic improvement of forest trees for biomass production by tissue culture. Biomass. 2:5-15.
    311. Clofarabine. Pediatric Drugs. 7:265-266.
    312. Idelalisib for the treatment of B-cell malignancies. Expert Opinion on Orphan Drugs. 3:109-123.
    313. Prevention and treatment of cancer. Anticancer Research. 36:4971-4975.
    314. Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells. Oncotarget. 7:39458-39472.
    315. ACS Symposium Series. 639:265-278.
    316. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. International Journal of Oncology. 47:782-790.
    317. Forodesine - Preclinical studies. Haematologica Reports. 2:35-37.
    318. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. European Journal of Medicinal Chemistry. 123:317-331.
    319. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leukemia and Lymphoma. 1-11.
    320. Decrease in total protein level of bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia. 30:1803-1804.
    GANDHI's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (760)
    Co-Authors (83)
    Similar People (60)
    Same Department Expand Description